Respiratory Reviews discusses a study which found that Xolair (omalizumab) provided good-to-excellent control of asthma symptoms in 70% of patients.

National Jewish Medical Center chronicles the development and potential benefits of the asthma therapy, also known as omalizumab or Xolair.

Doctor's Guide summarizes a study which found that the monoclonal antibody significantly improved asthma control in adult patients.